Skip to content
Screener

Globus Medical GMED Reportable Segment — Foreign currency transaction gain/(loss)

Similar metrics at other companies

comScore logo
SCORReportable Segment — Gain (loss) from foreign currency transactions
$1.24M+171%
BioCryst Pharmaceuticals logo
BCRXReportable Segment — Gain (Loss), Foreign Currency Transaction, before Tax
$27K+143%
XPEL, Inc. logo
XPELReportable Segment — Gain (Loss), Foreign Currency Transaction, before Tax
$403K-61.2%
Research Solutions logo
RSSSSingle Reportable — Foreign Currency Transaction Gain Loss Before Tax
-$12.53K-128%
Ur-Energy logo
URGSingle Reportable — Foreign Currency Transaction Gain Loss Before Tax
-$639K
Dogwood Therapeutics logo
DWTXSingle Reportable — Foreign Currency Transaction Gain Loss Before Tax
-$5.86K+74.8%

Other financials

Income statement

See full
Revenue$789.6M+5.9%
Gross profit$548.2M+10.4%
Operating income$182.4M+140%
Net income$151.6M-25.3%
EPS (diluted)$1.10-26.2%

Balance sheet

See full
Cash & equivalents$507.7M+121%
Total debt$112.3M-7.6%
Total equity$4.8B+11.0%
Total assets$5.5B+10.6%

Cash flow

See full
Operating cash flow$209.7M+169%
CapEx$33.2M-28.8%
Free cash flow$176.6M+464%

Valuation

See full
Market cap$10.93B+52.9%
Enterprise value$10.54B+49.6%
P/E20.4×+0.4×
P/S3.5×+0.8×

Profitability

See full
Gross margin68.5%+5.8pp
Operating margin20.3%+9.6pp
Net margin17%+3.4pp
FCF margin24%+3.9pp

Returns & leverage

See full
Return on equity11.8%+3.2pp
Debt / equity0.0×
Current ratio4.6×+0.5×

Where this comes from

Reported directly by Globus Medical in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The source filing: Globus Medical’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054450
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquisition-related costs(11,080)(33,155)(17,457)(34,213)
Amortization of intangibles(29,560)(30,189)(59,086)(58,991)
Other segment expenses (d)(13,827)(22,390)(29,100)(31,156)
Operating income/(loss)183,60376,881336,238174,598
Interest income/(expense), net7,07469312,5082,374
Foreign currency transactional gain/(loss)(860)38(2,973)4,308
Bargain purchase gain110,5611,118110,561
Income/(loss) before income taxes$189,817$188,173$346,891$291,841

Item 1. Financial Statements

FAQ

What is Globus Medical's reportable segment — foreign currency transaction gain/(loss)?
Globus Medical (GMED) reported reportable segment — foreign currency transaction gain/(loss) of -$860K in Q2 2026.
How has Globus Medical's reportable segment — foreign currency transaction gain/(loss) changed year-over-year?
Globus Medical's reportable segment — foreign currency transaction gain/(loss) decreased by 2363.2% year-over-year, from $38K to -$860K.
What does reportable segment — foreign currency transaction gain/(loss) mean?
This captures the impact of fluctuations in exchange rates on transactions denominated in currencies other than the segment's functional currency. It reflects the volatility inherent in international operations and the effectiveness of hedging strategies.

Ask your AI about Globus Medical's reportable segment — foreign currency transaction gain/(loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude